MCA reclassification
This article was originally published in The Tan Sheet
Executive Summary
First two products to be considered under Medicines Control Agency's new drug reclassification system are J&J Consumer Pharmaceuticals' Nizoral Dandruff Shampoo 2% (ketoconazole) and Pharmacia's Regaine Regular Strength (minoxidil 2%). Firms have applied to switch legal status from "Pharmacy" to "General Sale List," MCA says. J&J's Nizoral switched from Rx to pharmacy status in 1996; indications will be for "prevention and treatment of dandruff only," UK agency says. Pharmacia's Regaine will have "improved information on the pack, label and leaflet," as well as dedicated hot line, Web site. New reclassification strategy went into effect April 1 (1"The Tan Sheet" May 6, 2002, p. 4)...
You may also be interested in...
UK Drug Reclassification System May Double OTC Switches – Health Minister
The British government expects its new drug reclassification system to potentially double the number of medicines that switch from prescription to non-Rx status
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.